Media and methods for differentiating t cells from hematopoietic stem cells

Abstract

Embodiments of the disclosure include compositions and methods related to differentiate and engineer hematopoietic stem and progenitor cells (HSPCs or HSCs) to mature T cells (Diff-T cells) for off-the-shelf use for clinical therapy. Embodiments of the media are serum-free, and/or the culture methods are feeder-free. The Diff-T cell products can be conventional aP T cells, yS T cells, and unconventional T cells such as invariant natural killer T (iNKT) cells, non-invariant nature killer T (NKT) cells, mucosal-associated invariant T (MAIT) cells, and others. The Diff-T cell products can also be designed to be the CD8-positive or CD4-positive T cell subtypes, and the CD4-positive Diff-T cells can be further designed to be various TH-polarized subtypes.

Dependencies are inferred from the claim text.